PTC will use the network and life sciences capabilities of Blackstone to expand its business development works. Credit: mwooten / Pixabay.

PTC Therapeutics has signed a strategic financing partnership worth up to $1bn with funds managed by Blackstone to back the development of the former’s innovative product pipeline. 

Through the funding, PTC intends to attain a constant state of making available a minimum of one therapy every two to three years to continue to deliver transformative therapies to patients across the globe. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the deal, funds managed by Blackstone Life Sciences and Blackstone Credit will make initial funding worth $500m to PTC, which comprises $350m in low-cost, low-dilution capital at closing.

This alliance takes advantage of the several therapeutic platforms of PTC and its established track record of providing transformative therapies to patients with rare diseases. 

Translarna, Emflaza, Upstaza, sepiapterin and vatiquinone are used as collateral for the tailored senior secured term loan investment from Blackstone.

See Also:

PTC will use the network and life sciences capabilities of Blackstone to expand its business development works. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The deal includes $300m in senior secured debt for a period of seven years, $50m for the purchase of common stock of PTC, $150m in delayed draw debt for up to 18 months, as well as $500m in potential credit facility or other investment capital to back business development activities.

PTC Therapeutics chief financial officer Emily Hill said: “This strategic financing will support the acceleration of PTC’s robust and diversified pipeline, business development opportunities and general corporate purposes. 

“Our strong internal drug development and commercialisation efforts, a record of business development and value creation, combined with Blackstone’s network and life sciences expertise, puts PTC in a strong position to continue to execute our mission.”